AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
← catalyst calendarNCT06665165 · readout ≤ 193 d
Sponsored by Amylyx Pharmaceuticals Inc. (industry) · AMLX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
48estimated
Sites
14
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-07 | actual | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- ALS
Interventions
- Drug: AMX0114
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFEvaluate the safety and tolerability of AMX0114 in adult participants living with ALS
measured Day 1 - Day 145 (End of Study)
Permalink · AMLX's whole pipeline · Catalyst calendar · Every registered study · What changed